

No registration fees are used to fund entertainment or alcohol at this conference

Conference Program [Print](#) | [View meeting in 12 hr \(am/pm\) time](#)

The meeting will begin on Sunday, December 4 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, December 8 with a closing plenary session from 17:00 to 20:00, followed by a social hour and entertainment. We recommend return travel on Friday, December 9 in order to fully experience the meeting.

SUNDAY, DECEMBER 4

16:00–20:00	Arrival and Registration	Promenade
18:00–20:00	Welcome Mixer No registration fees are used to fund alcohol served at this function.	Promenade

MONDAY, DECEMBER 5

07:30–08:30	Breakfast	Pecos/Canyon
08:30–09:30	Welcome and Keynote Address Meeting has ended...abstracts no longer viewable online. * William E. Dowling , NIAID, National Institutes of Health, USA * Thomas W. Geisbert , University of Texas Medical Branch, USA Erica Ollmann Saphire , The Scripps Research Institute, USA <i>The Molecular Tool-Kit of Hemorrhagic Fever Viruses</i>	Mesa A-B
09:30–12:15	Innate Immune Evasion I Meeting has ended...abstracts no longer viewable online. * Erica Ollmann Saphire , The Scripps Research Institute, USA Christopher F. Basler , Georgia State University, USA <i>Ebola Virus VP35 and VP24 are Innate Immune Suppressors and Virulence Determinants</i> Coffee Break Elke Mühlberger , Boston University, USA <i>Silence Is Golden - Distinct Host Responses in Human Macrophages Infected with High or Low Pathogenic Ebolaviruses</i> Juan Carlos de la Torre , The Scripps Research Institute, USA <i>Novel Strategies to Developing Therapeutics and Vaccines to Combat Hemorrhagic Fever Arenaviruses</i> Ana Fernandez-Sesma , Mount Sinai School of Medicine, USA <i>Modulation of Innate Immunity by Dengue Virus</i>	Mesa A-B
12:15–14:30	On Own for Lunch	
12:15–13:00	Poster Setup	Mesa C
13:00–22:00	Poster Viewing	Mesa C
14:30–16:30	Workshop 1: Innate Immune Evasion II * Christopher F. Basler , Georgia State University, USA Gaya K. Amarasinghe , Washington University in St. Louis, USA <i>Role of Ebola Viral VP24 Protein in Immune Evasion</i> Hinh Ly , University of Minnesota, Twin Cities, USA <i>Molecular Mechanisms of Inhibition of Antigen-Presenting Cells by Human Hemorrhagic Fever-Causing Arenaviruses</i>	Mesa A-B

Colm Atkins, University of Texas Medical Branch, USA
Rift Valley Fever Virus Infection in Human Neuronal Cells

Daniel Stephen Chertow, National Institutes of Health, USA
Role of Ebola Virus Proteins in Bystander Lymphocyte Apoptosis

Lilia Melnik, Tulane University, USA
The Ebola Virus Delta-Peptide Has Viroporin-Like Activity

Jessica R. Spengler, Centers for Disease Control and Prevention, USA
Crimean-Congo Hemorrhagic Fever Virus Strain-Dependent Disease in Humanized Mice

Emily Speranza, Boston University, USA
Delineating Survival from Fatal Outcome in Ebola Virus Disease in Humans

16:30–17:00	Coffee Available	Promenade
17:00–19:00	Host Genetics Meeting has ended...abstracts no longer viewable online.	Mesa A-B
	* Cesar Muñoz Fontela , Heinrich Pette Institute, Germany <i>Dissecting Human Immunity to Ebola Virus</i>	
	Jan E. Carette , Stanford University, USA <i>Host Factors Involved in Pathogenesis of HFV</i>	
	Beatriz de la Caridad Sierra Vázquez , Pedro Kouri Institute for Tropical Medicine, PAHO/WHO Collaborating Center, Cuba <i>Short Talk: Lipid/Cholesterol Metabolism Involved in Viral Replication and Immune Response Provide African-Ancestry Protection Against Dengue Hemorrhagic</i>	
19:00–20:00	Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.	Pecos/Canyon
19:30–22:00	Poster Session 1	Mesa C

TUESDAY, DECEMBER 6

07:30–08:30	Breakfast	Pecos/Canyon
08:30–11:45	Endothelial Dysfunction and Coagulopathy I Meeting has ended...abstracts no longer viewable online.	Mesa A-B
	* Nigel Mackman , University of North Carolina at Chapel Hill, USA <i>Coagulation Cascade Activation during Viral Infection</i>	
	Lisa E. Hensley , NIAID, National Institutes of Health, USA <i>Late-Stage Filovirus Disease in NHPs</i>	
	Coffee Break	
	Anita K. McElroy , Emory University, USA <i>Endothelial Dysfunction and Coagulopathy during Ebola Virus Disease in Humans</i>	
	Stefan Kunz , Lausanne University Hospital, Switzerland <i>Molecular Mechanisms underlying Lassa Virus Invasion of Vascular Endothelial Cells</i>	
	Dennis A. Bente , University of Texas Medical Branch, USA <i>Crimean-Congo Hemorrhagic Fever Virus in of the Transmission and Pathogenesis: Current Considerations</i>	
11:45–14:30	On Own for Lunch	
11:45–13:00	Poster Setup	Mesa C
13:00–22:00		

Poster Viewing		Mesa C
14:30–15:30	<p>Workshop 2A: Endothelial Dysfunction and Coagulopathy II</p> <p>* Lisa E. Hensley, NIAID, National Institutes of Health, USA</p> <p>Roberto Aiolfi, The Scripps Research Institute, USA <i>Defective Platelet Thromboxane A2 Signaling and Serotonin Release in the Pathogenesis of Bleeding during Viral Infection</i></p> <p>Anne-Marie Connolly-Andersen, Umeå University, Sweden <i>Pulmonary Endothelial Glycocalyx Degradation in Hantavirus Infection</i></p> <p>Ashley St. John, Duke-NUS Medical School, Singapore <i>Dengue Virus-Elicited Tryptase Breaks Tight Junctions to Induce Endothelial Permeability and Shock</i></p> <p>Brian Martin Sullivan, The Scripps Research Institute, USA <i>Linking Platelet Dysfunction to Cytotoxic T Cell Responses during Lethal Viral Hemorrhagic Fever Infection</i></p>	Mesa A-B
15:30–16:30	<p>Workshop 2B: Clinical and Immunologic Findings during Lassa Infection</p> <p>* Colleen S. Kraft, Emory University, USA</p> <p>Aneesh K. Mehta, Emory University, USA <i>Novel Insights into the Clinical Care of Lassa Disease</i></p> <p>Anita K. McElroy, Emory University, USA <i>The Human Innate and Adaptive Immune Response to Lassa Virus Infection: A Case Study</i></p> <p>Lisa Oestereich, Heinrich Pette Institute, Germany <i>Human Immune Responses to Lassa Infection in Nigeria</i></p>	Mesa A-B
16:30–17:00	Coffee Available	Promenade
17:00–19:00	<p>Diagnostics Meeting has ended...abstracts no longer viewable online.</p> <p>* Jonathan S. Towner, Centers for Disease Control and Prevention, USA <i>Filovirus Replication in Naturally and Experimentally Infected Bats</i></p> <p>Stephan Günther, Bernhard-Nocht-Institut für Tropenmedizin, Germany <i>Diagnosis of Ebola Virus Disease during the Outbreak in West Africa</i></p> <p><u>John H. Connor</u>, Boston University School of Medicine, USA <i>Short Talk: Real-Time Visualization of Individual Hemorrhagic Fever Virions in Solution</i></p> <p>Frederick Holtsberg, Integrated Biotherapeutics, USA <i>Short Talk</i></p>	Mesa A-B
19:00–20:00	<p>Social Hour with Lite Bites</p> <p>No registration fees are used to fund alcohol served at this function.</p>	Pecos/Canyon
19:30–22:00	Poster Session 2	Mesa C

WEDNESDAY, DECEMBER 7

07:30–08:30	Breakfast	Pecos/Canyon
08:30–11:30	<p>Vaccines I Meeting has ended...abstracts no longer viewable online.</p>	Mesa A-B

* **Connie S. Schmaljohn**, US Army Medical Research Institute of Infectious Disease, USA

Michael Egan, Profectus Biosciences, USA
Filovirus rVSV Vaccines

Sheri Dubey, Merck & Co., Inc., USA
Clinical Development of a Recombinant Ebola Vaccine in the Midst of an Unprecedented Outbreak

Coffee Break

Heinz Feldmann, Rocky Mountain Laboratories, USA
Lassa rVSV Vaccines

Andrea Marzi, NIAID, National Institutes of Health, USA
Short Talk: Efficacy of VSV-EBOV Post-Exposure Treatment in Rhesus Macaques Infected with EBOV-Makona

Farshad Guirakhoo, GeoVax, Inc., USA
Short Talk: MVA-VLP Platform for Development of a Single Dose Tetravalent Vaccine against Hemorrhagic Fever Viruses

Igor Lukashevich, University of Louisville, USA
Short Talk: Reassortant ML29 Vaccine Platform to Control Lassa Fever in West Africa

11:30–17:00

On Own for Lunch

11:30–13:00

Poster Setup

[Mesa C](#)

13:00–22:00

Poster Viewing

[Mesa C](#)

16:30–17:00

Coffee Available

[Promenade](#)

17:00–19:00

Vaccines II

Meeting has ended...abstracts no longer viewable online.

[Mesa A-B](#)

* **Heinz Feldmann**, Rocky Mountain Laboratories, USA

Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA
The Live Attenuated Dengue Vaccines TV003 and TV005 Completely Protect Against DENV-2 Infection in a Controlled Dengue Human Challenge Model

Shinji Makino, University of Texas Medical Branch, USA
Development of a Single-Cycle Replicable Rift Valley Fever Virus Vaccine

Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA
Clinical Assessment of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome (HFRS)

Courtney Brooke Woolsey, University of Texas Medical Branch, USA
Short Talk: A Recombinant Vesicular Stomatitis Virus-Based Vaccine Mediates Post-Exposure Protection against Marburg Virus Angola in Rhesus Macaques

19:00–20:00

Social Hour with Lite Bites

No registration fees are used to fund alcohol served at this function.

[Pecos/Canyon](#)

19:30–22:00

Poster Session 3

[Mesa C](#)

THURSDAY, DECEMBER 8

07:30–08:30

Breakfast

[Pecos/Canyon](#)

08:30–11:45

Therapeutics I

Meeting has ended...abstracts no longer viewable online.

[Mesa A-B](#)

* **Andrea Marzi**, NIAID, National Institutes of Health, USA

Larry Zeitlin, Mapp Biopharmaceutical, Inc., USA
Junin and Filovirus mAb Therapeutics

Thomas W. Geisbert, University of Texas Medical Branch, USA
Filovirus siRNA Therapeutics

Coffee Break

Luis M. Branco, Zalgen Labs, LLC, USA
Lassa Virus Human Monoclonal Antibody Therapeutics

Eric Bergeron, Centers for Disease Control and Prevention, USA
Short Talk: Antiviral Activity and Mechanism of Action of Site-1 Protease (S1P) Inhibitor on Crimean-Congo Hemorrhagic Fever Virus

Zachary Bornholdt, Mapp Biopharmaceutical, USA
The Structure-Based Design of a Pan-ebolavirus Immunotherapeutic Cocktail

Anna Z. Wec, Adimab LLC, USA
Short Talk: Bispecific Antibodies Targeting the Intracellular Virus-Receptor Interaction Provide Broad in vivo Protection Against Ebolaviruses

Bronwyn M. Gunn, Massachusetts General Hospital, USA
Short Talk: Antibody Fc-Effector Functionality Predicts Monoclonal Antibody-Mediated Post-Exposure Protection against Ebola Virus Challenge

11:45–17:00

On Own for Lunch

16:30–17:00

Coffee Available

[Promenade](#)

17:00–19:15

Therapeutics II

Meeting has ended...abstracts no longer viewable online.

[Mesa A-B](#)

* **Chad E. Mire**, Galveston National Laboratory, USA

Brian Gowen, Utah State University, USA
Prospects for Treatment of Severe Arenavirus and Bunyavirus Infections

M. Javad Aman, Integrated Biotherapeutics, Inc., USA
Short Talk: Cross-Protection Against Ebolaviruses with Vaccine Elicited Broadly Neutralizing Monoclonal Antibody Cocktails: Evidence for Cooperative Neutralization

Travis K. Warren, US Army Medical Research Institute of Infectious Diseases, USA
In vivo Efficacy of BCX4430 Against Ebola Virus

John Misasi, NIAID, National Institutes of Health, USA
Protective Monotherapy Against Ebola Infection: Structure and Molecular Basis of Potent Neutralization

Ami Patel, Wistar Institute, USA
Short Talk: DNA-Delivery of Monoclonal Antibodies (DMABs) as an Alternative, in vivo mAb Delivery Platform against Ebola Virus Infection

20:00–21:00

Social Hour with Lite Bites

No registration fees are used to fund alcohol served at this function.

[Promenade/Mesa Ballroom](#)

20:00–23:00

Entertainment

Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

[Mesa Ballroom](#)

FRIDAY, DECEMBER 9

Departure

*Session Chair †Invited, not yet responded.

We gratefully acknowledge support for this conference from:

Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

[Click here](#) to view all of the donors who support the Directors' Fund.

Keystone Symposia thanks our Sponsor for generously supporting this meeting:



We gratefully acknowledge the generous grant for this conference provided by:

National Institutes of Health

[National Institute of Allergy and Infectious Diseases \(NIAID\)](#)

Grant No. 1R13AI126804-01

Funding for this conference was made possible [in part] by 1 R13 AI 126804 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Mapp Biopharmaceutical, Inc.

Merck Vaccine Division

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

[Click here to view more of these organizations](#)

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

[Click here to view more of these organizations](#)

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org, Phone: +1 970-262-2690

[Click here](#) for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,

